 
 
 
 
 
 
 
 
 
 
 
Niclosamide for Patients with Mild to Moderate Disease  
from Novel Coronavirus (COVID -19) 
Principal Investigator:  Harry Selker, MD  
 0120 2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of Changes  from Previous Version:  
 
Affected 
Section(s)  Summary of Revisions Made  Rationale  
Protocol Title  Addition of asymptomatic patients  1. FDA 
recommendation  
Study Synopsis  Addition of Day 21 fecal specimen, 
addition of asymptomatic 
participants, addition of Wellforce 
and Clinical Research Network 
(CRN) sites for recruitment . 
Study duration 2 months, study 
completion 4 months   1. FDA 
recommendation  
2. Recruitment 
optimization  
3. Decreased 
numbers of daily 
COVD positive 
patients  
Section 3.0  
Objectives and 
endpoints  The primary objective of this study 
is to determine if a course of 
treatment with niclosamide 
improves respiratory viral clearance 
compared to treatment with 
placebo . 1. Viral shedding 
endpoint  
Section 4.0  
Study design  Reduction in  fecal viral shedding as 
measured by fecal PCR on days, 3, 
7, 10, 14 . Day 21 fecal specimen 
added.  1. FDA 
recommendation  
Section 4.3  
Justification of 
Dose  Additional literature and 
background added  1. FDA 
recommendation  
Section 5.1  
Inclusion 
Criteria  Physical assessment data removed.  
No need for oxygen 
supplementation added.  
 1.  Virtual 
recruitmen t  
5.2 Exclusion 
Criteria  
 Systemic treatments removed as 
exclusion.   1. FDA 
recommendation  
5.3 Lifestyle 
considerations  
 Advisement to avoid alcohol  added  
 1. FDA 
recommendation  
5.5 Strategies 
for recruitment 
and retention  
 1. Updates to include Wellforce 
and CRN sites  
2. Twenty -dollar ($20) ClinCard 
payment at each specimen 
collection timepoint  
3. Update to recruitment with 
community outreach, study 
information distribution and 
nurses script  
 1. Recruitment 
enhancement  
2. Time and effort of 
participants for 
specimen 
collection  
 
 
 
6.1.1. Study 
Intervention  
 Day 21 fecal specimen added  
Additional data on oropharyngeal 
specimen collection added  
 1. FDA 
recommendation  
6.2.2 
Formulation, 
Appearance, 
Packaging and 
Labeling  
 Study drug specific information 
added as provided by Bayer 
Pharmaceuticals  
 1. Updated as per 
IND 
6.2.3 and 6.2.4 
Product storage 
and preparation  
 Changed to blister packaging  
 1. Updated as per 
IND 
7.2 Participant 
discontinuation/ 
withdrawal 
from study  
 Revised  
 1. FDA 
recommendation  
8.1 Efficacy 
assessments  
 Baseline and screening (Day 0)  
Record COVID symptoms, if 
symptomatic  
Record number of days since onset 
of symptoms, if symptomatic  
Follow -up Evaluation  
• Collect temperature and oximetry 
data daily, with the caveat that if 
O2 goes below 92%, an addition 
oximeter reading should be taken 2 
hours later.  ADDED :  If the follow -
up O2 saturation remains below 
92%, the participant will be r eferred 
to their Primary Care Physician 
(PCP) or to the local Emergency 
Department  
•Collect fecal samples for viral 
shedding Day 21 added  
Early  Termination/Hospitalization     1. FDA 
recommendation  
 
A 30 -day follow -up call and AE 
assessment for those patients who 
are hospitalized will be performed.  
 
 
8.3.7 Reporting 
of pregnancy  
 Additional information added re: 
pregnancy and breast feeding  
 1. FDA 
recommendation  
10.1.6  Safety 
Oversight  
 Independent Safety Monitor and 
stopping rules added  
 1. FDA 
recommendation  
4.1 Overall 
Study Design   Addition of affiliate site recruitment 
detail  1. Reliance 
affiliate  
1.1 Study 
Synopsis  Primary endpoint change  1. Primary Efficacy 
Endpoint: 
Respira tory viral 
clearance at Day 
3.  
 
1.2 Schedule of 
activities  Addition of +/1 1 -day windows  1. Increase options for 
participant study 
visits  
 
4.1 Overall 
study design  
 Increase sample size to n=200   
1. The current 
positivity rate on 
Day 1 of ~40% 
results in ITT 
sample size of 200.    
 
5.1 Exclusion 
Criteria  Add:  History of receipt of COVID -19 
vaccine  1. Potential effect of 
vaccine on viral 
shedding  
5.2 Strategies 
for Recruitment  Added: Newton Wellesley Hospital, 
Maine Medical Center and New 1. Agreed to 
distribute study 
brochures  and 
posters  
 
 England  Quality Care Alliance 
(NEQCA)  
6.1 Study 
Intervention  Removed:  Transport  by courier 
service to the Tufts Medical Center  
Telemedicine Platform  
Removed: Amwell  
Added: A HIPPA compliant 
telehealth platform; e.g., Doximity, 
will be used to conduct remote 
study visits.  
Added: COVID positive list 
generated twice daily  1. No contact FedEx 
pickup/  delivery 
to CLIA certified 
lab  
2. Doximity platform 
used  
 
9.1 Statistical 
Hypothesis  Sample size calculation revision  1. Sample size 
increase  
9.2 Sample Size 
Determination  Revised  1. Increase d 
sample size  
9.3 Populations 
for analysis  Modified Intention -to-Treat 
Analysis Dataset  modified  1. Sample size 
increase  
9.4 Statistical 
Analysis  Revised analysis of the primary 
endpoint  1. Sample size 
increase  
  
Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  1 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  1 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  1 
SchemA  3 
1.2 Schedule of Activities (SoA)  ................................ ................................ ................................ ...............  4 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ............  5 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .... 5 
2.2 Background ................................ ................................ ................................ ................................ ...........  6 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ....................  7 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ..... 7 
2.3.2  Known Potential Benefits  ................................ ................................ ................................  7 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ................................  8 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ ................  8 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ .............  9 
4.1 Overall Design  ................................ ................................ ................................ ................................ ...... 9 
4.2 Scientific Rationale for Study Design ................................ ................................ ..............................  10 
4.3 Justification for Dose  ................................ ................................ ................................ .........................  10 
4.4 End of Study Definition  ................................ ................................ ................................ .....................  11 
5 STUDY POPULATIOn  ................................ ................................ ................................ ................................ . 12 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................  12 
5.2 Exclus ion Criteria  ................................ ................................ ................................ ...............................  12 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ....................  12 
5.4 Screen Failures  ................................ ................................ ................................ ................................ .. 12 
5.5 Strategies for Recruitment and Retention  ................................ ................................ ......................  13 
6 STUDY INTERVENTION  ................................ ................................ ................................ ............................  13 
6.1 Study In tervention(s) Administration  ................................ ................................ ...............................  13 
6.1.1  Study Intervention Description  ................................ ................................ .....................  13 
6.1.2  Dosing and Administration  ................................ ................................ ............................  15 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ................  15 
6.2.1  Acquisition and accountability  ................................ ................................ ......................  15 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ................................ ................  16 
6.2.3  Product Storage and Stability  ................................ ................................ .......................  16 
6.2.4  Preparation  ................................ ................................ ................................ ......................  16 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................ ...........................  16 
6.4 Study Intervention Compliance  ................................ ................................ ................................ ........  17 
6.5 Concomitant Therapy  ................................ ................................ ................................ ........................  17 
6.5.1  Rescue Medicine  ................................ ................................ ................................ ............  17 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAl.  ................................ ................................ ................................ ....................  18 
7.1 Discontinuation of Study Intervention  ................................ ................................ .............................  18 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............................  18 
7.3 Lost to Follow -Up ................................ ................................ ................................ ...............................  19 
8 STUDY ASSE SSMENTS AND PROCEDURES  ................................ ................................ .....................  19 
8.1 Efficacy Assessments  ................................ ................................ ................................ .......................  19 
8.2 Safety and Other Assessments  ................................ ................................ ................................ .......  21 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ...............  21 
  
8.3.1  Classification of an Adverse Event.  ................................ ................................ .............  22 
8.3.2  Time Period and Frequency for Event Assessment and Follow -Up .......................  23 
8.3.3  Adverse Event Reporting  ................................ ................................ ..............................  23 
8.3.4  Serious Adverse Event Reporting  ................................ ................................ ...............  24 
8.3.5  Reporting Events to Participants  ................................ ................................ .................  24 
8.3.6  Events of Special Interest  ................................ ................................ .............................  24 
8.3.7  Reporting of Pregnancy  ................................ ................................ ................................  24 
8.4 Unanticipated Problems  ................................ ................................ ................................ ....................  24 
8.4.1  Definition of Unanticipated Problems (UP): ................................ ................................  24 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ................  25 
8.4.3  Reporting Unanticipated Problems to Pa rticipants  ................................ ...................  25 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  25 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .......................  25 
9.2 Sample Size Determination  ................................ ................................ ................................ ..............  25 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  26 
9.4 Statistical Analyses ................................ ................................ ................................ ............................  26 
9.4.1  General Approach  ................................ ................................ ................................ ..........  26 
9.4.2  Analysis of the Secondary Endpoint(s)  ................................ ................................ .......  27 
9.4.3  Safety Analyses  ................................ ................................ ................................ ..............  27 
9.4.4  Baseline Descriptive Statistics  ................................ ................................ .....................  27 
9.4.5  Planned Interim Analyses  ................................ ................................ .............................  28 
9.4.6  Sub-Group Analyses  ................................ ................................ ................................ ..... 28 
9.4.7  Tabulation of Individual participant Data  ................................ ................................ .... 28 
9.4.8  Exploratory Analyses  ................................ ................................ ................................ ..... 28 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ..............................  28 
10.1  Regulatory, Ethical, and Study Oversight Considerations . ................................ ..........................  28 
10.1.1  Informed Consent Process  ................................ ................................ ...........................  28 
10.1.2  Study Discontinuation and Closure  ................................ ................................ .............  30 
10.1.3  Confidentiality and Privacy  ................................ ................................ ...........................  30 
10.1.4  Future Use of Data  ................................ ................................ ................................ .........  31 
10.1.5  Key Roles and Study Governance  ................................ ................................ ..............  31 
10.1.6  Safety Oversight  ................................ ................................ ................................ .............  32 
10.1.7  Clinical Monitoring  ................................ ................................ ................................ ..........  33 
10.1.8  Quality Assurance and Quality Control  ................................ ................................ .......  34 
10.1.9  Data Handling and Record Keeping.  ................................ ................................ ...........  34 
10.1.10  Protocol Deviations  ................................ ................................ ................................ ........  35 
10.1.11  Publication and Data Sharing Policy  ................................ ................................ ...........  35 
10.1.12  Conflict of Interest Policy  ................................ ................................ ..............................  35 
10.2  Additional Considerations  ................................ ................................ ................................ .................  36 
10.3  Abbreviations  ................................ ................................ ................................ ................................ ...... 37 
10.4  Protocol Amendment History  ................................ ................................ ................................ ...........  39 
11 REFERENCES  ................................ ................................ ................................ ................................ .............  40 
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   1 STATEMENT OF COMPLIA NCE  
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 
Practice ( ICH GCP) and the following :  
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 
National Institutes of Health ( NIH)-funded investigators and clinical trial site staff who are responsible 
for the conduct, management, or oversight of NIH -funded clinical trials  have completed Human Subjects 
Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recr uitment materials, and all participant materials will be 
submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both the 
protocol and the consent form must be obtained before any participant is enrolled.  Any amendment to 
the protocol will require review and approval by the IRB before the changes are implemented to the 
study.  In addition, a ll changes to the consent form will be IRB -approved; a determination will be made 
regarding whether  a new consent needs to be obtained f rom participants  who provided consent , using a 
previously approved consent form . 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  Niclosamide for Patients with Mild to Moderate Disease from Novel 
Coronavirus (COVID -19) 
 
Study 
Description : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This study will evaluate the antihelmintic drug, niclosamide, as a potential 
treatment for mild to moderate coronavirus disease 2019 ( COVID -19).  
Niclosamide, which has potent antiviral activity against single -stranded RNA 
viruses including coronaviruses, was proposed as an antiviral during the SARS 
outbreak in 2002 and has activity including SARS -CoV-2 where it was found to 
inhibit SARS coronavirus, SARS -CoV, in in vitro  studies and similarly structured 
RNA viruses (both in vitro  and in vivo ).  We hypothesize that the antiv iral activity 
of Niclosamide may be extended to COVID -19. 
Objectives:   
  Primary Objective: To evaluate the efficacy of niclosamide in shortening 
contagious period as determined by time to viral clearance.  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   2  Secondary Objectives:  To evaluate the efficacy of niclosamide in mitigating 
clinical outcomes and shortening duration of symptoms resulting from 
COVID -19 infection . 
 
 
Endpoints:                             Primary Efficacy Endpoint: Respiratory viral clearance at Day 3.  
 Secondary Efficacy Endpoints:   
 Fecal viral clearance at Day  14. 
 Reduction in viral shedding as measured by oropharyngeal swab on days 
1, 3, 7, 10, 14  
 Reduction in fecal viral shedding as measured by fecal PCR on days 1, 3, 
7, 10, 14 , 21  
 Progression to se vere COVID, as a composite endpoint defined as O2 
saturation <92% on room air in two consecutive measurements at least 2 
hours apart OR requirement of hospitalization OR need for artificial 
ventilation OR death.  
 Time to resolution of fever  
Safety endpoint:  incidence of Adverse Events (AEs)  
Study Population:  
 Patients 18 years of age or older who are  COVID -19 (SARS -CoV-2) positive  by PCR 
who are asymptomatic or have  mild to moderate symptoms of COVID infection.  
 
 
Phase:  Phase II  
Description of 
Sites/Facilities  
 
Enrolling 
Participants:  
 Study participants will be recruited for participation from Tufts Medical Center , 
Wellforce and Clinical Research Network (CRN) sites.    
 
Participants will be identified as those re porting to Tufts  Medical Center,  
Wellforce and CRN sites for outpatient COVID -19 testing.  Patients with SARS -
CoV-2 positive test results will be provided the optio n to participate in our study . 
The Study Team will enroll and randomize patients into the study after the 
patient has a confirmed positive test result and meets all the inclusion and none 
of the exclusion criteria.   
 
Additional sites and/or social media may be used to enhance recruitment.  The 
study will be listed at www.clinicaltrials.gov . 
 
 
Description of 
Study 
Intervention:  Participants in the treatment arm will receive niclosamide 2 grams orally once 
daily for 7 days in addition to current standard of care treatment.  Those in the 
control group will receive placebo by mouth in the same numbers of pills on day 
1 and daily for 6 more days (total 7 days of treatment) in addition to current 
standard of car e treatment.  Fecal samples and oropharyngeal swab samples will 
be collected for viral shedding as measured by PCR on days 3, 7, 10, 14  and 21  
(fecal sample only) .  A baseline fecal and oropharyngeal sample will be obtained 
on Day 1 prior to starting dosin g of niclosamide/ placebo.  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   3  
 
Study Duration:  The study is estimated to complete enrollment within 2-month s of initiation of 
enrollment;  however, enrollment will remain open until the study goal is met. 
The duration of the entire project is anticipated to be a maximum of 4 months.  
 
 
Participa nt 
Duration:  Individual participant will complete all participant visits within 30 days.   Adverse 
events will be monitored and collected by the Study Team from the point of 
signed consent until 7 (for non -serious adverse events ) or 30 days (for  serious 
adverse events ) after the last day of study participation.   
SCHEM A 
 
 
 

NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   4 1.2 SCHEDULE OF ACTIVITIES (SOA)  
 
 Screen  
& 
Baseline  
Day 0  Treat  
Day 1  
 
+/- 1 day  Treat  
Day 2  
 
+/- 1 day  Treat  
Day 3  
 
+/- 1 
day Treat  
Days 4 -6 
 
+/- 1 day  Post -
Treatment  
Day 7  
 
+/- 1 day  Post -
Treatment  
Day 10  
 
+/- 1 day  Post -
Treatment 
Day 14 *  
 
+/- 1 day  30-day 
Safety Call  
 
+/ - 1 Day  
  
Confirmed 
COVID -19 + test  X         
Medical/  
Social  
History 
(Demographics)  
 X         
Inclusion/ 
Exclusion  
Criteria  X         
Informed 
Consent  X         
Assign Subject 
ID X         
Randomize  X         
 Initiation of Study  
Dose treatment 
group with 2g 
niclosamide or 
placebo   X X X X     
Provide sample 
collection 
packet, 
thermometer, 
and finger -tip 
pulse oximetry   X        
 Participant reporting and sample collection  
AE reporting   X X X X X X X X 
O2 & Temp 
reporting   X X X X X X X X 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   5  
* An additional AE assessment and fecal specimen will be collected at day 21  
 
 
2  INTRODUCTION  
 
2.1 STUDY R ATIONALE   
The ongoing COVID -19 pandemic is an urgent public health crisis with few if any rapid and practical 
solutions.  The outbreak of COVID -19 has been declared to be a public health emergency of international 
concern by the World Health Organization (WHO), and the development of effective therapies for fast -
spreading fatal COVID -19 is in an urgent need.  Given the seriousness  and time -sensitive nature of this 
highly contagious virus, the medical and scientific communities must work quickly and efficiently to find 
a feasible way to address this global emergency.   
Niclosamide is an anthelminthic drug that has been widely used i n humans to treat tapeworm infections 
for several decades and is currently listed on the WHO List of Essential Medicines , the safest and most 
effective medicines needed in a health system. There are no current proven treatments for COVID -19, 
and significan t efforts are going toward developing novel therapeutics that have not been assessed for 
safety in humans.  There are a number of existing drugs prescribed for other indications that have 
demonstrated potent antiviral activity  [1-3].  In a recent study, Niclosamide  exhibited antiviral activity 
against SARS -CoV-2, the strain responsible for the current COVID -19 pandemic  [3]. That niclosamide  has 
already demonstrated efficacy in specifically inhibiting SARS -CoV-2 replication in vitro is  incredibly 
promising.   
A recent study evaluated clinical samples from 73 hospitalized patients with SARS -CoV-2 infection. In 39 
of those patients, their fecal samples tested positive for SARS -CoV-2 RNA, with 17 of those patients 
remaining SARS -CoV-2-positive in feces after becoming negative in respiratory samples  [29].  Taken 
together, this suggests that both the commonly accepted route of infection through the respiratory 
system as well as the GI tract are implicated in the pathogenesis of COVID -19-related disease 
manifestations.  
While severe acute respiratory sy ndrome (SARS) coronavirus 2, SARS -CoV-2-infected patients most 
commonly present with fever, tiredness and dry cough; a subset of these patients present with 
gastrointestinal (GI) issues [2]. Importantly, a recent study found that fecal viral shedding conti nues 
nearly 5 weeks after the last detection of SARS -CoV-2 RNA in respiratory samples, suggesting that the GI 
tract serves as a viral reservoir and allows for prolonged COVID -19 infection and transmission  [4]. Given 
that SARS -CoV-2 is so highly contagious and can be easily spread by both respiratory droplets and fecal -
oral route  [5], limiting its transmission is paramount to public health. These data suggest that there is a Oropharyngeal 
& fecal sample 
collection   X 
(prior to 
dosing)   X  X X X  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   6 critical need to develop practical COVID -19 intervention strategies to treat SARS -CoV-2 infection and to 
prevent person -to-person transmission . 
Repurposing reliable and effective drugs for COVID -19 therapy is not only a safer strategy but will also 
allow for more rapid introduction into clinical practice.  For this reason, we propose to u se the widely 
used antihelmintic drug, Niclosamide  for treatment of COVID -19.  
2.2 BACKGROUND   
SARS -CoV-2 has been shown to invade human tissues via the angiotensin converting enzyme II receptor 
(ACE2), which is highly expressed on cell types found in various tissues  [30]. In a study to identify 
potential routes of infection for the SARS -CoV virus corresponding to the outbreak in China in 2002, a 
remarkable finding was the high surface expression of ACE2 protein on human lung alveolar epithelial 
cells and enter ocytes, the simple columnar epithelial cells lining the inner surface of the small and large 
intestines[30].   
This is not the first time that this small molecule (niclosamide ) has been proposed as a therapeutic for 
this specific application.  Shortly afte r the SARS outbreak in China in 2002 -2003, niclosamide  was tested 
for its potential use as an antiviral medication. Perhaps somewhat surprisingly, niclosamide  was found 
to inhibit SARS coronavirus, SARS -CoV, in in vitro studies [14]. Later studies went on to evaluate its 
potential in combating coronavirus in vivo [31]. Fortunately, the SARS outbreak subsided rather quickly, 
and as a result, no future interventi ons were necessary.  
Multiple studies have studied the antiviral capacity of niclosamide  in treating other similarly structured 
pathogenic viruses.  During the outbreak of the Zika virus (ZIKV), another positive -sense RNA -based virus 
similar to the coronav irus family, Niclosamide  was again identified as a potential antiviral therapeutic, 
with ZIKV -inhibiting effects both in vitro [13] as well as in a humanized in vivo model of ZIKV -induced 
microcephaly [5]. Upon reviewing the literature, we found that niclosamide  was also able to inhibit 
production of a variety of viral strains [4, 7, 8, 10 -12, 15, 32], including adenovirus [10], dengue [4] and 
chikungunya virus [11]. Its mechanism of action in this capacity is to increase the pH within acidic 
endosomes of h ost cells, thereby inhibiting virus entry and release.  
In addition to its antihelmintic and antiviral properties, niclosamide  has also demonstrated anti -bacterial 
[8, 33, 34], anti -inflammatory [16, 17] and anti -cancer activity [18, 19, 23, 33, 35 -40]. Moreover , 
niclosamide  has also shown promise for treating respiratory illness [14, 18, 20 -22] even functioning as a 
bronchodilator in an in vivo mouse model of asthma [21, 22].  
Niclosamide  has demonstrated efficacy as a cancer therapeutic in both animal mode ls [19, 36] as well as 
human clinical trials [23, 35]  which  suggests that in addition to potentially being efficacious in this anti -
COVID -19 capacity, Niclosamide  is also likely to induce few complications as it is tolerated well even in 
immunocompromised cancer patients.   
In the current pandemic crisis, medical professionals are understandably focused more on stabilizing the 
very sick. However, if niclosamide  could work in any way to halt or prevent infection in the less sick (or 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   7 even in the uninfected), it would be monumental in terms of returning to normal life.   Because the drug 
is inexpensive and has few if any side effects, taking Niclosamide  prophylactically might help to prevent 
COVID -19 spreading.  Even if this treatment does not completely eradica te infection, niclosamide  
treatment may help to decrease viral load, thereby allowing the host immune system to better combat 
the disease.  
2.3 RISK/BENEFIT ASSESSM ENT   
2.3.1  KNOWN  POTENTIAL RISKS  
Niclosamide has been  used since mid of the 1960s as an antihelmintic  drug which inhibits glucose 
uptake, oxidative phosphorylation and anaerobic metabolism .  Niclosamide has few side effects and is 
known to be well tolerated even when applied over a long period [19]. Reported a dverse effects of 
Niclosamide are mild and inf requent. This may include GI disturbances, lightheadedness, malaise, and 
pruritus. Alcohol may enhance the absorption of niclosamide , increasing the risk of side effects and 
therefore should be avoided when taking this drug.    
Pregnancy and breastfeeding a re not exclusion criteria.  The FDA categorizes medications based on 
safety for use during pregnancy. Five categories - A, B, C, D, and X, are used to classify the possible risks 
to an unborn baby when a medication is taken during pregnancy.  
 
Niclosamide f alls into category B:  
• There are no well -done studies that have been done in humans with Niclosamide. But in animal 
studies, pregnant animals were given this medication, and the babies did not show any medical issues 
related to this medication.  
• Studies in women suggest that this medication poses minimal risk to the infant when used during 
breastfeeding.  
2.3.2  KNOWN POTENTIAL BENE FITS  
 
Niclosamide  is an oral medication that has been used to treat tapeworm infestations since 1960[6]. It is 
on the World Health Organization (WHO) List of Essential Medicines, the safest and most effective 
medicines needed in a health system  [6]. In addition to its orig inally prescribed use, Niclosamide  has 
been repurposed for a variety of clinical applications.  Niclosamide  has demonstrated antiviral activity 
both in vitro and in vivo on a variety of single stranded RNA -based viral strains  [4, 5, 7 -13] and even 
SARS -CoV, a previous strain of coronavirus associated with the SARS outbreak in China in 2002[14]. Even 
more recently, Niclosamide  was shown to inhibit SARS -CoV-2, the strain responsible for the current 
COVID -19 pandemic  [3]. Its mechanism of action in this capaci ty is to increase the pH within acidic 
endosomes of host cells, thereby inhibiting virus entry and release [4, 11, 15]. In addition to its 
antihelmintic and antiviral properties, Niclosamide  has also demonstrated anti -inflammatory activity 
[16, 17], and ha s shown promise for treating respiratory illness  [18-20] even functioning as a 
bronchodilator in an in vivo mouse model of asthma [21, 22]. Furthermore, that Niclosamide  has been 
utilized in a variety of human clinical trials to enhance chemotherapeutics i n cancer treatment [19, 23 -
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   8 25] suggests that is likely to induce few complications as it is tolerated well even in 
immunocompromised cancer patients.   
 
2.3.3  ASSESSMENT OF POTENT IAL RISKS AND BENEFITS  
The primary goal is to maximize patient safety. To fulfill this goal, Tufts and the study team will take 
every measure to reduce patient risk of COVID -19-related complications, which includes the following:  
• Reduction of in -patient and outpatient face - to face visits to limit amount of exposure to 
patient and related populations  
• Use of a courier service to provide study materials  and no pickup and delivery FedEx to obtain 
patient samples required for this study  
• Extensive patient screening prior to enrollment to ensure that all enrolled patients meet 
inclusi on/exclusion criteria; more specifically to avoid enrollment of COVID -19 patients already 
severely ill due to this disease .  A screening and enrollment log will be maintained.  
There is no expectation of severe adverse outcomes or reactions due to a patient  bein g treated with 
niclosamide .  Niclosamide  is generally well tolerated and has been prescribed clinically for over 30 years.  
Reported AEs in current use are mild and include nausea and diarrhea. All participants will be given 
access to contact informat ion of the Study Team, and any adverse reactions will be reported as required 
by the protocol.   
 
3 OBJECTIVES AND ENDPO INTS  
 
The primary objective of this study is to determine if a course of treatment with niclosamide improves 
respiratory viral clearance compared to treatment with placebo.  
 
Secondary objectives include comparing the viral shedding from fecal samples and severity of clinical 
outcomes between treatment groups.  
 
Primary Efficacy Endpoint:  
 Respiratory viral clearance at Day 3.  
 
Secondary Efficacy Endpoints:   
 Fecal viral clearance at Day 14. 
 Reduction in viral shedding as measured by oropharyngeal swab on days, 3, 7, 10, 14  
 Reduction in fecal viral shedding as measured by fecal  PCR on days, 3, 7, 10, 14 and 21  
 Progression to severe COVID, as a composite endpoint defined as O2 saturation <92% on room 
air in two consecutive measurements at least 2 hours apart OR requirement of hospitalization 
OR need for artificial ventilation OR death.  
 Time to resolution of fever  
Safety endpoint : incidence of AEs  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   9 4 STUDY DESIGN  
4.1 OVERALL  DESIGN  
 
This is a double -blinded randomized controlled trial of 200  adult outpatients with mild to moderate 
symptoms of COVID -19 not requiring hospitalization.  Participants will be identified as those reporting to 
Tufts Medi cal Center seeking COVID -19 testing.  All patient s will be provided the option to participate in 
our study pending a positive SARS -CoV-2 test result. The Study Team will enroll and randomize patients 
into the study after the patient has a confirmed positive test result and meets all the inclusion and none 
of the exclusion criteria.   
Participants in the treatment arm (n= 100) will receive niclosamide  2g orally daily for 7 days in addition 
to current standard of care treatment.  Those in the control group (n= 100) will receive placebo by 
mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment) in 
addition to current  standard of care treatment.  
Laboratory PCR testing will be performed at Tufts Medical Center laboratory  or other CLIA certified lab . 
Study participants will be recruited for participation from Tufts Medical Center . Associated sites at 
Newton -Wellesley Hospital, Melrose Wakefield and Lowell General Hospital as well as CRN sites will be 
included in recruitment and engaged as deemed necessary by the Study Team  to ensure identification 
and reporting of maximum number of positive cases and p rompt patient engagement / enrollment .   
 
A study recruitment brochure will be distributed at the associated Wellforce and CRN sites.  A study 
poster will be available for affiliated outpatient sites that perform COVID testing.  Both will include a QR 
code for ease of accessing study information.  In addition, nurses who provide results to patients (by 
phone) who have tested positive at Tufts Medical Center outpatient will provide basic, scripted study 
information to potential participants.  This information  will include contact information for the Study 
Team and has been submitted to the Tufts IRB.  Participation at Wellforce and CRN sites will be limited 
to distribution of study brochures and display of posters and (on a site by site basis) provision of PHI  
(name and contact phone number of potential participants who express interest in the study).  This 
information will be provided to the Tufts Study Team via a secure, encrypted message.   Revisions to the 
study brochure or any recruitment material will be provided to the site contact by the Tufts Study Team.   
No research activities will be conducted at the associated sites (e.g., informed consent, study visits, data 
collection, data entry, data analysis, etc.).  All study activity will be conducted by the Tufts Study Team.  
The Tufts Study Team will keep record of the site of origin for each enrolled study participant.  This de -
identified, aggregated recruitment data will be provided to each site as requested by the site.  
 
A study recruitment brochure will  be distributed in the community.  A study poster will be available for 
affiliated outpatient sites that perform COVID testing.  Both will include a QR code for ease of accessing 
study information.  In addition, nurses who provide results to patients (by p hone) who have tested 
positive will provide basic, scripted study information to potential participants.  This information will 
include contact information for the Study Team and has been submitted to the Tufts IRB.  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   10 Potential participants will initially be identified as those reporting to Tufts Medical Center , Wellforce or 
CRN  outpatient .  The Study Team will enroll and randomize patients into the study after the patient has 
a confirmed positive test result and meets all the inclusion and none of the  exclu sion criteria.  
 
Participants who provide informed consent and meet all of the inclusion and none of the exclusion 
criteria will be randomized on Treatment Day 0 in a 1:1 ratio to either the Treatment Group or the 
Control Group, in accordance with a computer -generated schedule prepared by a biostatistician.  The 
randomization schedule will be incorporated into the REDCap E lectronic Data Capture (EDC)  system.  
Randomization will then be performed by study personnel directly in the EDC system.  Study pe rsonnel 
will be instructed not to randomize until participant has been confirmed to meet all inclusion/exclusion 
criteria on treatment day 0.  
 
4.2 SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
 
Randomized double -blind placebo control (RDBPC) studies provide the stron gest possible evidence of 
causation.  Phase II trials are used to determine the efficacy and safety of an intervention in participants 
with the disease for which a new intervention is proposed.  Randomization in combination with blinding 
helps to avoid pos sible bias in the selection of participants, their assignment to an intervention or 
control, and the analysis of their response to the intervention.   
 
4.3 JUSTIFICATION FOR DO SE 
The standard oral dosage of Niclosamide prescribed for Hymenolepis nana tapeworm infestation (e.g. 
adults —maximum of 2 grams/day for seven days) is clinically efficacious in this antiviral capacity. Based 
on previous antiviral studies of Niclosamide  both in v itro and in vivo [5, 13, 14] , the average required 
dosage to achieve antiviral activity is 1 uM, which corresponds to ~0.327 µg/ml. In a recent clinical trial 
to test efficacy of Niclosamide  as an antimetastatic therapy [23, 24] , clinicians found that upon oral 
intake, Niclosamide  Cmax plasma level peaked to a median of 0.665 µg/ml ( ranging from 0.429 to 0.848 
µg/ml ), suggesting that traditional oral drug delivery should be sufficient t o inhibit SARS -CoV-2 
production.  Repeated dosing is commonly used when treating an infection where viruses may (at the 
time of ingestion) be at various stages of attachment, invasion, and replication.   
Importantly, human infections with SARS -CoV-2 have demonstrated two  known reservoirs of the virus.  
Viremia tends to be relatively uncommon, with viral replication largely occurring in the respiratory and 
gastrointestinal systems [37, 38] . The few cases in which SAR -CoV-2 titers are detectable in plasma ha ve 
been reported in those patients already progressed to severe disease requiring hospitalization [39]. 
Plasma levels are limited both by oral absorption, but also by high plasma protein binding.  In Bayer 
simulations Cmax levels reaching almost 1200 nmol/ l, or 1.2 uM is predicted.  There is 99% plasma 
protein binding.  Though free drug concentrations may not exceed the IC50 in plasma, we do not 
anticipate viral burden in the plasma to be a significant contributor  to disease or spread of virus.  
While we firmly believe that standard oral delivery of Niclosamide  will be sufficient to achieve anti -
COVID -19 activity, it is important to address certain issues previously posed with regard to the 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   11 pharmacokinetics of this drug. The inaugural publication describing studies of Niclosamide  in human 
subjects reported that upon a single oral dose of 2g carbonyl -14C-labeled Niclosamide , up to 25% of 14C-
activity was detected in urine while the remainder was eliminated in feces [31] suggesting that 
Niclosamide  may be preferentially sequestered in the GI tract. Other studies have also suggested a 
similar biodistribution of Niclosamide  in the colon [34]. Oral delivery of Niclosami de in mice infected with 
an epidemic strain of Clostridium difficile, inhibited disease pathogenesis by targeting host mechanisms 
to prevent pathogen entry into intestinal epithelia without disrupting the endogenous gut 
microbiota [34]. With increasing insights emerging into the critical role of GI involvement in COVID -19 
severity and tran smission, this potential sequestration of Niclosamide  in the gut could likely be 
beneficial for both treatment strategies as well as prevention of transmission.   
The second major viral reservoir, the respiratory tract, may be a key site of activity for th e niclosamide. 
Though lung tissue and epithelial lining fluid concentrations are not available, there is measurable 
activity in the respiratory tract.  In a transgenic mouse model of asthma, niclosamide treatment (13 
mg/kg/day) reduced mucus production, br onchoconstriction, and inflammation of airway tissues. 
Assuming the average human weighs approximately 62kg, our dosing strategy of 2g/day, is the 
equivalent of approximately 32mg/kg/day, which is significantly higher and likely to have similar effects. 
In addition, systemic delivery of niclosamide (20mg/kg) significantly enhanced efficacy of 
chemotherapeutic drugs in an in vivo mouse model of non -small cell lung cancer [40], further 
demonstrating that niclosamide can specifically target the lung in vivo . 
4.4 END OF STUDY DEFINITION  
 
A participant is considered to have completed the study if he or she has completed all phases of the 
study including the last visit or the last scheduled procedure shown in the Schedule of Activities , Section 
1.2. 
 
Early Termination /Hospitalization  
All participants have the right to withdraw from study participation at any time during the study. If, for 
whatever reason, a participant withdraws from the study  or is hospitalized for increased severity of 
COVID symptoms or other cause , an Early Termination Visit will be performed  as deemed feasible by 
the PI or physician I nvestigator.   
 
Any AE , SAE  or other medical condition or situation that occurs such that continued participation in the 
study would not be in the best interest of th e participant  will result in early termination.  
 
The following procedures will be performed at  the Early Termination  Visit: 
 Assess for AEs 
 Assess for complications following treatments  
 Document all current medications, including medications over the counter  and herbal 
medications  
 Perform clinical assessment (as deemed feasible if hospitalized)  
 Evaluate for increased severity of COVID -19-related disease   
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   12  
If clinical evaluation is deemed not  feasible due to patient condition, the Study Team will colle ct as much 
of the Early Termination Visit data via the Electronic Medical Record  as is available.  
 
5 STUDY POPULATIO N 
5.1 INCLUSION CRITERIA  
 
In order to be eligible to participate in this study, an individual must meet all the following criteria:  
• SARS -CoV-2 infection confirmed by PCR ≤ 3 days before randomization  
• Provision of informed consent  
• Stated willingness to comply with all study procedures and availability for the duration of the 
study  
• Male or female, over 18 years of age  
• No need for oxygen supplement ation  
• No requirement for hospitalization at the time of enrollment  
• Ability to take oral medication and be willing to adhere to the Niclosamide /placebo regime n 
 
5.2 EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this study:  
• Known allergic reactions to components of the  niclosamide  
• Participation in another trial or use of any experimental treatment for COVID -19, including 
chloroquine, hydroxychloroquine, remdesivir, and lopinapir/ritonavir  
• History  of receipt of COVID -19 vaccine *  
• Current hospitalization or requiring hospital admission at screening  
 
* If a participant is enrolled in the study and then  subsequently has an appointment for the COVID -19 
vaccine , they will remain on study and will be advised that they can keep their vaccine appointment. 
Vaccine administration will be noted and considered in the final data analysis.  
 
5.3 LIFESTYLE CONSIDERAT IONS  
 
No special preparations or additional steps (for example, special diets, fasting, other medicin es, 
laxatives, or enemas) are necessary before, during, or immediately after taking niclosamide . Participants 
are advised to avoid al cohol consumption during the study treatment period.  
 
5.4 SCREEN FAILURES  
 
Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently randomly assigned to the study intervention or entered in the study. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure participants , to 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   13 meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, screen 
failure de tails, eligibility criteria, and any SAE.  
 
5.5 STRATEGIES FOR RECRU ITMENT AND RETENTION  
 
Participants will be identified as those outpatients reporting to Tufts Medical Center, Wellforce or our 
CRN sites seeking COVID -19 testing. Any asymptomatic patient and those with mild to moderate COVID -
19 symptoms not requiring hospital admission or supplemental oxygen, will be provided the opti on to 
participate in our study once they have a reported positive SARS -CoV-2 test result.  Lowell General, St. 
Elizabeth’s, Newton Wellesley Hospital , Maine Medical Center  and New England  Quality Care Alliance 
(NEQCA)  have agreed to distribute our study brochure at the time of testing at their drive thru testing 
and ambulatory locations. These sites will also be displaying our study poster (with QR code) in the ED, 
Primary Care clinics.  Additional Wellforce and CRN sites may be used to enhance recruitment.  Study 
brochures and promotional material will be given to potential participa nts at each of the testing sites 
including st udy team contact information.  The study brochure will be given to the patient at the time of 
COVID - 19 testing, by the testing site personnel. The participant will proactively contact the study team 
if interested in participation following a positive COVI D-19 test.   
 
The Study Team will enroll and randomize patients meeting the above criteria into the study after the 
patient has a confirmed positive test result and meets all of the inclusion and none of the ex clusion 
criteria.   
 
Tufts Commu nity Health Improvement Program  will incorporate the distribution of study material 
(brochure)  with their general COVID -19 materials within the Chinatown community and residential 
towers.  The Tufts Medical Center (TMC) Symptom Clinic, staffed by TC registered nurses (RNs), will be 
contac ting patients who test positive by phone. The RN will give a brief (scripted ) overview of the study 
and contact information for the study team  at the time of call to provide testing result.  
 
Social media will be used to enhance recrui tment.  This study will be listed at www.clinicaltrials.gov . 
 
Participants will be offered  twenty dollars ( $20) for time and effort (via ClinCard) at each specimen 
collection timepoint (Days 1, 3, 7, 10, 14 and  21). 
 
All research activity including Informed Consent will be performed by Tufts Medical Center employees.   
 
6 STUDY INTERVENTION  
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   14 Informed Consent will be obtained , all the inclusion and none of the exclusion criteria are met .   
 
In addition to  niclosamide  or placebo treatments, all enrolled patients will be provided a home 
thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both 
temperatu re at oxygen saturation at the time of daily oral administration of drug.   The relatively low 
reported percentage of error for the finger probe supports  that the finger probe is the modality of 
choice to measure intermittent oxygen saturation in the outpat ient setting.   
 
Oropharyngeal and fecal swabs will be collected at days 1 (baseline), 3, 7, 10, and 14 of the study. An 
additional fecal specimen will be collected at day 21. In the case of oropharyngeal samples, care will be 
taken to ensure that sampling methods are consistent for each individual patient across all included 
timepoints, to limit any bias due to potential differences in viral load.   
 
Oropharyngeal collection is  minimally invasive and can reliably be self -administered.  Recent research 
testing SARS -CoV-2 detection, nasopharyngeal and oropharyngeal (saliva) samples from confirmed                    
SARS -CoV-2 found that oropharyngeal yielded greater detection sens itivity and consistency throughout 
the course of infection. Less variability in self -sample collection was also found. This research 
demonstrated that oropharyngeal samples are a viable and more sensitive alternative to 
nasopharyngeal swabs and can enable at-home self -administered sample collection for accurate SARS -
CoV-2 testing [41, 42 ].  
 
The collection of oropharyngeal samples will be directly observed by a Study Team member via the 
telehealth platform.  The participant will open the viral transport kit  and swab the back of the throat and 
tonsil area (avoiding mouth, teeth, and gums) and place to swab back into the vial.  For fecal specimen, 
the participant will swab feces from a plastic container (or wrap) placed on the toilet seat.  Printed 
instruction s will be provided to each participant with detail on how to collect both the oropharyngeal 
and fecal specimens.  These instructions will also be reviewed with the participant by a member of the 
Study Team.  
 
Once obtained, samples will be transported by no contact pickup and delivery FedEx  service to the Tufts 
Medical Center or CLIA - certified lab to prevent unnecessary hospital visits and to encourage compliance 
given the self -quarantine status of enrolled patients.    
 
Telemedicine  Platform  
 
A HIPPA compl iant telehealth platform; e.g., Doximity, will be used to conduct remote study visits.  
 
Twice daily a list of COVID -19 positive patients will be generated by the Tufts Medical Center lab and 
provided  to the Study Team  via a secure Tufts email account.  Upon receiving the COVID -19 positive test 
notification, COVID -19 positive participants will be approached remotely by a study Investigator  for 
remote (telephone) Informed Consent .  Once consent  is obtained , all the i nclusion and no ne of the  
exclusion crite ria are met , the study CRC will engage with the participant to enroll  them  in the tele health  
platform and schedule the  follow -up telehealth  study appointment s.   
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   15  
If the participant does not have a Smartphone, one will be provided to them  along with the ot her study 
materials .   A prepaid USPS envelope with additional instructions will be provided to send the package 
through the USPS for return.  Participants will be guided thru the step -by-step tele medicine  setup on 
their Smartphone by the study CRC .  Scripted guidance will be provided to the study CRCs  to ensure that 
instructions provided to participants are consistent.  For example, included in the script, the study CRC 
will provide instruction in simple, easy to understand language such as, “ I am going to take a minute and 
walk you through signing up for the app so you are ready on your visit date.  “I’ve have actually gone 
ahead and scheduled the visit for you in the app ”.  The app is navy blue, has a picture of a doctor with a 
stethoscope and ligh ter blue heart”.    Once set up, a reminder of the upcoming appointment will be sent 
to the participant via email and text  message .   
 
Once the participant “checks - in” for their study visit , the CRC, investigator,  or Study Team member will 
receive a notice  that the participant is in the Waiting Room .  A family member or other support person 
of the participant ’s choice can be included in any/all visits via Facetime.  More than one study team 
member can also join the appointment as needed  or desired  with the “Add Person”  Facetime 
number/ address.  Once the study team enters the Waiting Room , a split screen clearly displays the 
patient, support person and the study team member(s).    
6.1.2  DOSING AND ADMINISTR ATION  
 
Participants eligible for the study will review and undergo informed consent at the time they receive 
confirmation of positive SARS -CoV-2 test result.  After obtaining consent, participants will be randomly 
assigned on a 1:1 basis to receive:   
 
 Treatment Group blinded:  Will receive niclosamide 2g  orally  daily for 7 days in addition to 
current standard of care  
 Control Group blinded:  Will receive placebo by mouth daily for 7 days in addition to current 
standard of care   
 
Niclosamide may be taken on an empt y stomach (either 1 hour before or 2 hours after a meal). 
However, to prevent stomach upset, it is best taken after a light meal (for example, breakfast).  
Participants will be advised to avoid alcohol consumption during study treatment period.  
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY     
6.2.1  ACQUISITION AND ACCO UNTABILITY  
 
In accordance with recent COVID -19 FDA Guidance, if scheduled visits at clinical sites are significantly 
impacted, certain IP, such as those that are typically distributed for self-administration, may be 
amenable to alternative secure delivery methods.   As such:  
 
Niclosamide and placebo (Investigational Product, IP) will be stored in the Tufts Medical Center 
Investigational Pharmacy.  Upon enrollment, the investigational pharma cy will package and dispense the 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   16 IP to the patient, along with the sampling kit.  The entire supply of study medication will be dispensed at 
one time.  It will be delivered to the subject via courier service.  Subjects will be asked to document 
compliance with study protocol in a subject diary.  If a subject does not use all the IP, the remainder 
shall be returned to the study investigators with the day 14 samples.  The IP will then be returned to the 
manufacturer or destroyed on site.  
 
Investigational new  drug application (IND) submitted under section 505(i) of the Federal Food, Drug, and 
Cosmetic Act (FDCA) for Niclo samide chewable tablets, 500 mg has been approved:  FDA IND # 151423 . 
 
Placebo manufacturer  KABS Laboratories Inc.  See Appendix A  for manufac turing detail.  
 
 
6.2.2  FORMULATION, APPEARA NCE, PACKAGING, AND LABELING  
 
Niclosamide will be provided as 500 mg chewable tablets.  They are gray -yellow round tablets with FE 
printed on one side and the “Bayer Cross” on the other side.  The excipients include: corn  starch, talc, 
sodium lauryl sulphate, povidone, vanillin, magnesium stearate, saccharin sodium .  They will be 
provided in blister packages for ease of use and enhanced stability.  They will be labeled as “Niclosamide 
OR Placebo,” with adequate adminis tration instructions prior to dispensing to subjects.   
 
6.2.3  PRODUCT STORAGE AND STABILITY  
 
Niclosamide and the placebo are oral tablets.  They can be stored at room temperature, 25°C (77°F) with 
excursions permitted to 15 -30°C (59 -86°F).  They will be dispens ed in blinded blister packaging.    
 
6.2.4  PREPARATION  
There will be no significant preparation.  Both niclosamide and placebo tablets will be dispensed in 
blinded blister packages and labeled in accordance with state and federal regulation.  
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING  
 
Participants who sign informed consent and meet all inclusion and exclusion criteria will be randomized 
on Treatment Day 0 in a 1:1 ratio to either the Treatment Group or the Control Group, in accordance 
with a computer -generated schedule prepared by a biostatistician.  The randomization schedule will be 
incorporated into the REDCap EDC system.  Randomization will then be performed by study personnel 
directly in the EDC system.  Study personnel will be instructed not to ran domize until participant has 
been confirmed to meet all inclusion/exclusion criteria on treatment day 0.  
 
As all members of the Study Team will be blinded, Tufts Investigational Drug Services (IDS)  will be 
unblinded and will dispense both the Niclosamide and placebo. The study intervention ( niclosamide) 
and placebo will be packaged and as indistinguishable as possible .   
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   17 Refer to Section 9, Statistical Considerations  for sample size calculations.  
 
6.4 STUDY INTERVENTION  COMPLIANCE  
During the Baseline and Screening  (Day  0), the Principal Investigator (PI) or a co -Investigator will review 
the study with the participant and obtain informed consent and Health Insurance Portability and 
Accountability Act of 1996 (HIPAA) authorization .  A second member  of Study Team  (e.g., the study 
Clinical research coordinator (C RC)) will serve as a witness to the informed consent.   After the informed 
consent is obtained, the participant will be assigned a unique enrollment number. The subject will then 
be randomized to treatment in EDC  and provided blinded treatment (either Niclosamide  or placebo) and 
other study materials via  courier .  
On Treatment Day  1, a member of the Study Team or study CRC  will review the dosing and schedule of 
Niclosamide / placebo .   
• The patient will be instructed to record all do ses in Study Drug Administration Diary  
• During each tele health  visit, the study CRC or other Study Team member will review the diary 
with the participant  
• The pa rticipant  will be advised not to discard any study pill bottles  
• Baseline AEs, O2 saturation, temperature, oropharyngeal & fecal sample collection will be 
obtained  
 
Refer to the Section 1.2, Schedule of Activities.  
 
6.5 CONCOMITANT THERAPY  
 
Concomitant therapies are any new or existing medications or therapy taken by the patient including:   
 Drugs, including but not limited to, prescription, over the counter, birth control 
pills/patches/hormonal devices, and homeopathic preparations  
 Nondrug t herapies, including but not limited to, thermal/laser/radiation procedures, vitamins, 
herbal medicines/supplements.  
 
During the Screening process, information on all concomitant therapies, medications, and procedures 
will be recorded in the source document s and appropriate Case Report Form (CRF)  along with the 
diagnosis or reason for use. Once the patient receives the first dose of study drug, recording of 
concomitant therapies will be limited to any new medication or modification of an existing medication 
taken for treatment of an AE. These therapies will be recorded in the source documents and appropriate 
CRF along with the diagnosis or reason for use. Those therapies used for the treatment of an adverse 
event are to be linked to an AE and documentation of  the AE must also be completed  
 
6.5.1  RESCUE MEDICINE  
The study site will not  supply rescue  medication . 
   
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   18 7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT  
DISCONTINUATION /WITHDRAWA L.  
7.1 DISCONTINUATION  OF STUDY INTERVENTIO N 
 
This study may be temporarily suspended or prematurely terminated if there is enough  reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be 
provided by the suspending or terminating party to the study t eam, the Sponsor and the Institutional 
Review Board (IRB), as appropriate.  If the study is prematurely terminated or suspended, the study 
team will promptly inform the IRB and will provide the reason(s) for the termination or suspension.  
 
Discontinuation  from niclosamide  does not mean discontinuation from the study, and remaining study 
procedures should be completed as indicated by the study protocol.   If a clinically significant finding is 
identified (including, but not limited to changes from baseline) after enrollment, the investigator or 
qualified designee will determine if any change in participant management is needed. Any new clinically 
relevant finding will be reported as an AE. 
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
All participants are free to withdraw from participation at any time, for any reason, specified or 
unspecified, and without prejudice.  Reasonable attempts will be made by the Investigator to provide a 
reason for participant withdrawals. The reason for the  participant’s withdrawal from the study will be 
specified in the participant’s source documents and the CRF. The study team will make every effort to 
contact participants who are lost to follow -up. Attempts to contact such participants will be 
documented in the participant’s records (e.g., times and dates of attempted telephone contact, receipt 
for sending a registered letter, etc.).  
 
A participant will be discontinued from the study for the following reasons only:  
• Participant withdrawal of consent  
• Lost to  follow -up 
• Participant death  
• Hospitalization for severe COVID - 19 symptoms  
The following procedures will be performed at the Early Termination  visit : 
 Assess for AEs  
 Assess for complications following treatments  
 Document all current medications, including medications over the counter and herbal 
medications  
 Perform clinical assessment (as deemed feasible if hospitalized)  
 Evaluate for increased severity of COVID -19-related disease  
  
If clinical evaluation is deemed not feasible due to patient condition, the Study Team will collect as much 
Early Termination Visit  data as possible from  the Electronic Medical Record  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   19  
The reason for participant discontinuation  or withdrawal from the study  will be recorded on the CRF.   
 
7.3 LOST TO FOLLOW -UP 
 
A participant will be considered lost to follow -up if he or she fails to complete more than (2) scheduled 
telehealth visits and is unable to be contacted by the study staff .  
 
The following actions must be taken if a participant fails to attend a required telehealth visit : 
 The Study Team  will attempt to contact the participant and reschedule the missed visit and 
counsel the participant on the importance of maintaining the assigned visit schedule and 
ascertain if the participant wishes to and/or should continue in the study.  
 Before a participant  is deemed lost to follow -up, the investigator or designee will make every 
effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, 
a certified letter to the participant’s last known mailing address or local equiv alent methods). 
These contact attempts will be documented in the participant’s medical record or study file.  
 Should the participant  continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason o f lost to follow -up. 
 For participants considered lost to follow -up, the CRF will be completed up to the last contact 
with the participant.  
 
8 STUDY ASSESSMENTS AN D PROCEDURES  
8.1 EFFICACY ASSESSMENTS  
 
The specific timing of procedures/evaluations to be done at each study visit are found in Section 1. 2, 
Schedule of Activities .  All assessment will be performed by the study investigators or a qualified 
member of the study team.  
 
Baseline and Screening  (Day  0) 
The following procedures will be performed at the Baseline/Screening visit:  
 Review the study with the participant and obtain written informed consent and Health 
Insurance Portability and Accountability Act of 1996 (HIPAA) authorization  
 Assign the p articipant a unique enrollment number  
 Review and record medical history, surgical history, and medication history to determine 
eligibility based on inclusion/exclusion criteria  
 Record smoking history  
 Record demographics (age, race, ethnicity, gender)  
 Docu ment all current medications, including medications over the counter  and herbal 
medications  
 Record COVID symptoms , if symptomatic  
 Record confirmation of positive SARS -CoV-2 test result  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   20  Record number of days since onset of symptoms, if symptomatic  
Randomiz ation and Treatment (Day  0) 
 Confirm patient meets all inclusion and none of the exclusion criteria  
 Randomize subject to treatment in EDC  
 Provide blinded treatment (either niclosamide  or placebo) and other study materials via courier  
 
Follow -Up Evaluation  
Remote clinical follow -up will occur at the following time points: Days 1, 2, 3, 7, 10 , 14, 21 and 30 .  
The following procedures will be performed at all follow -up visits, expected to be done by tele -medical 
methods, unless otherwise noted:  
 Assess for AEs  
 Assess COVID signs and symptoms  
 Document all current medications, including medications over the counter  and herbal 
medications  
 Document patient’s status as an outpatient, subsequently hospitalized, or died  
 Perform clinical assessment by patient report an d vital signs  (temperature and oxygen 
saturation)  
 Evaluate for increased severity of COVID -19-related disease  
 Collect temperature and oximetry data daily, with the caveat that if O2 goes below 92%, an 
addition oximeter reading should be taken 2 hours later .  If the follow -up O2 saturation remains 
below 92%, the participant will be referred to their Primary Care Physician (PCP) or to the local 
Emergency Department.  
 Collect oropharyngeal swab samples for viral shedding on days 1, (baseline) , 3, 7, 10, 14 (cou rier 
transport of specimen ) 
 Collect fecal samples for viral shedding as measured by fecal  PCR on days  1, (baseline) , 3, 7, 10, 
14 and 21 (courier  transport of specimen ) 
 
Final Study Visit (Non -hospitalized Participants)  
The following procedures will be performed at the final post treatment visit:  
 Assess for AEs 
 Assess for complications following treatments  
 Document all current medications, including medications over the counter  and herbal 
medications  
 Perform clinical assessment to evaluate for increased severity of COVID -19-related diseases  
 
Early  Termination/Hospitalization     
All participants have the right to withdraw from study participation at any time during the study. If, for 
whatever reason, a participant withdraws from the study  or is hospitalize d, an Early Termination Visit 
will be performed.  
 
The following procedures will be performed at the Early Termination  Visit : 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   21  Assess for adverse events  
 Assess for complications following treatments  
 Document all current medications, including medications over the counter and herbal 
medications  
 Perform clinical assessment (as deemed feasible if hospitalized)  
 Evaluate for increased severity of COVID -19-related disease   
 
If clinical evaluation is deemed not feasible due to patient condition, the Study Team w ill collect Early 
Termination Visit data via the Electronic Medical Record . 
A 30 -day follow -up call and AE assessment for those patients who are hospitalized  will be performed.  
8.2 SAFETY AND OTHER ASSESSMENTS  
 
For Study procedures and evaluations to be done as part of the study to monitor safety and support the 
understanding of the study intervention’s safety  refer to  Section 1. 2, Schedule of Activities and Section 
8.1 Study Assessments.  
   
8.3 ADVERSE EVENTS AND S ERIOUS  ADVERSE EVENTS  
 
Adverse event data will be summarized for all participants in the safety population. Site -reported serious 
adverse events and unexpected adverse drug reactions will be summarized as participant -based counts 
and percentages by AE category.  MedDRA system organ class and preferred term In addition, participant 
listings will be provided for serious, unexpected, and unanticipated adverse reactions. Any adverse 
events leading to discontinuation of study drug or death will also be listed for all p articipants.  
 
Definition of Adverse Event (AE)  
An AE is defined as any unanticipated medical occurrence regardless to relationship of the investigative 
arm of the trial. An AE can be any unintended sign, lab abnormality, symptom, or disease associated 
with the trial. Any abnormality that presents during a medical test are to be defined as an AE if it 
produces clinical signs and/or symptoms, requires intervention, or deemed clinically significant by the 
Investigator.  
 
The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will  be utilized for AE reporting 
the following study - specific AEs: 
 Cough  
 Dyspnea  
 Hypoxia  
 Nausea  
 Vomiting  
 Abdominal pain  
 Pruritus  
 Loss of appetite  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   22  Dizziness  
 Skin rash  
 
Definition of Serious Adverse Event (SAE)  
 
An AE is considered serious if it results in any of the following:  
 results in death;  
 is life -threatening (places the subject at immediate risk of death from the event as it occurred);  
 requires inpatient hospitalization or prolongation of existing hospitalization;  
 results in a persistent or significant disability/incapacity;  
 results in a congenital anomaly/birth defect; or  
 any other adverse event that, based upon appropriate medical judgment, may jeopardize the 
subject’s health and may require medical or surgical in tervention to prevent one of the other 
outcomes listed in this definition  
 
Definition of Unexpected Adverse Reaction (UAE)  
An adverse reaction, the nature or severity of which is not consistent with the  applicable product 
information (e.g. Product Informa tion/Summary of  Product Characteristics). This would include any SAE 
on health or safety, any life -threatening problem or death caused by, or associated with a drug; or any 
other unanticipated serious problem associated with a drug that relates to the righ ts, safety, or welfare 
of subjects.  
 
8.3.1  CLASSIFICATION OF AN  ADVERSE E VENT . 
8.3.1.1  SEVERITY OF EVENT  
 
All AEs will be assessed by the study clinician using the CTCAE V. 5.0  
 Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
 Grade 2 :  Moderate; minimal, local or noninvasive intervention indicated  
 Grade 3 :  Severe or medically significant but not immediately lif e-threatening; hospitalization or 
prolongation of hospitalization indicated  
 
8.3.1.2  RELATIONSHIP TO STUD Y INTERVENTION  
A Study Team physician will oversee the evaluation of patient reported severity of AEs using the 
following categories:  
Relationship to Study Products  
All AEs must have their relationship to study intervention assessed by the clinician who examines and 
evaluates the participant based on temporal relationship and his/her clinical judgment. The degree of 
certainty about causality will be graded using the categories below.  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   23 Definitely:  
 The relationship of the AE and the drug or the study procedure can be 
established.  
 
Probably:  
 While a clear relationship to the drug or to the study procedure cannot be 
established, the AE is associated with an expected AE or there is no other 
medical condition or intervention, wh ich could explain the occurrence of such 
an event.  
 
Possibly:  
 There is no clear relationship between the AE and the drug or study procedure; 
however, one cannot conclude  that there is no relationship.  
 
Unrelated:  
 There is no relationship between the AE  and the drug or study procedure.  This 
may include but is not limited to the incident being an expected outcome of a 
previously existing or concurrent disease, concomitant medication or 
procedure the participant experienced.  
 
 
8.3.1.3  EXPECTEDNESS  
Study Team members who are  clinically  qualified  (e.g., a physician co - Investigator)  will be responsible 
for determining whether an AE is expected or unexpected. An AE will be considered unexpected if the 
nature, severity, or frequency of the event is not consistent with the risk information previously 
described for the study products. This information will be provided to the IRB, to the Study Sponsor, and 
to any relevant governmental agency with regulatory or public health authority.  
8.3.2  TIME PERIOD AND FREQ UENCY FOR EV ENT ASSESSMENT AND F OLLOW -UP 
 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care . 
 
All AEs including local and systemic reactions not meeting the  criteria for SAEs will be captured on the 
appropriate CRF. Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to study product (assessed only by those with the training and 
authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while 
on study must be documented appropriately regardless of relationship. All AEs will be followed to 
adequate resolution.  
 
8.3.3  ADVERSE EVENT REPORT ING  
Adverse event data will be summarized for all participants in the safety population. Serious adverse 
events and unexpected adverse drug reactions will be summarized as participant -based counts and 
percentages by AE category . In addition, participant listings will be provided for serious, unexpected, 
and unanticipated adverse reactions. Any adverse events leading to discontinuation of study drug or 
death will also be listed for all participants.  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   24  
8.3.4  SERIOUS ADVERSE EVEN T REPORT ING  
 
Study team member s who are qualified will immediately report any serious adverse event, whether or 
not considered study intervention related, including those listed in the protocol  and must include an 
assessment of whether there is a reasonable possi bility that the study intervention caused the event. 
Study endpoints that are SAEs  must be reported in accordance with the protocol .   
 
8.3.5  REPORTING E VENT S TO PARTICIPANTS  
 
AEs, SAEs and UPs will be reported to IRB as outlined in Sections 8.3.5, 8.3.6 and 8.4.2 
 
8.3.6  EVENTS OF SPECIAL IN TEREST  
 
N/A 
 
8.3.7  REPORTING OF PREGNAN CY  
 
During the Informed Consent discussion, the MD study Investigator will ask women of childbearing 
potential if they are pregnant.  That yes/ no response will be recorded.  We will not exclude  women who 
are of childbearing years or pregnant.  We will collect pregnancy status information at the time of 
enrollment.  Niclosamide is a Category B (animal studies show no risks, but there are no controlled 
studies in pregnant women). Category B drugs include prenatal vitamins, acetaminophen and several 
other medications used routinely and safely during pregnancy.   
 
In addition to recording whether women of childbearing age are pregnant at the time of study 
enrollment, we will also record their breastfeeding status. For enrolled subjects who are pregnant or 
breastfeeding, we will include  follow up a specific query for any adverse effects on pregnancy and/or 
breastfeeding infant during the course of the study.  
 
8.4 UNANTICIPATED PRO BLEMS  
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP) : 
 
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to 
participants or others to include, in general, any incident, experience, or outcome that meets all the 
following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the Institutional Review Board ( IRB)-
approved research protocol and informed con sent document; and (b) the characteristics of the 
participant population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may h ave been caused by the 
procedures involved in the research); and  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   25 • Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
8.4.2   UNA NTICIPATED PROBLEM R EPORTING  
 
The investigator  will report unanticipated problems ( UPs) to the reviewing Institutional Review Board 
(IRB).  The UP report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or  outcome 
represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:   
• UPs that are SAEs will be reported to the IRB within 5 working days of the investigator becoming 
aware of the event.  
• A Study Team evaluation of an UP wil l be performed with a report of results of such evaluation 
will be provided to the reviewing IRB by the PI within 5 working days.  
• All other Reportable New Information will be reported to the IRB as per the policy.  
 
8.4.3  REPORTING UNANTICIPA TED PROBLEMS TO PARTICIPANTS  
 
AEs, SAEs and U Ps will be reported to IRB as outlined in Sections 8.3.5, 8.3.6 and 8.4. 2 
 
9 STATISTICAL CONSIDER ATIONS   
9.1 STATISTICAL HYPOTHES ES 
 
The null hypothesis is that the proportion of participants with respiratory viral clearance at Day 3 is the 
same in both treatment groups. The alternative hypothesis is that they are different.  
  
 
9.2 SAMPLE SIZE  DETERMINATION  
 
For the primary efficacy endpoint of respiratory virologic clearance at Day 3 measured by oropharyngeal 
viral shedding we assume that on Day 3, 50% of participants in the niclosamide  group who have a 
positive result on Day 1 (prior to dosing) will have a negative test results and 15% in the placebo group.    
With 40 particip ants  per group we have 89% power to show a statistically s ignificant difference 
between groups at Day 3 using Fisher’s Exact test at the two -sided 0.05 significance level .  Assuming that 
40% of randomized participants have a positive respiratory test result, 200 participants will be requi red 
to be randomized into the study.  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   26 9.3 POPULATIONS FOR ANALYSES  
 
 Intention -to-Treat (ITT) Analysis Dataset (all randomized participants)  
 Modified Intention -to-Treat Analysis Dataset (participants who took at least one dose of study 
intervention , have a positive test result on Day 1  and have Day 3 oropharyngeal  sample results 
available for analysis.  
 Safety Analysis Dataset: participants who took at least one dose of study intervention  
 Per-Protocol Analysis Dataset: subset of the participants in the full a nalysis (ITT) set who took at 
least 80% of study intervention and had no protocol violations that would affect the primary 
efficacy endpoint.  
 Other Datasets  that may be used for sensitivity analyses  
 
9.4 STATISTICAL ANALYSES  
9.4.1  GENERAL APPROACH  
 
Baseline demogra phic and clinical characteristics and other results will be summarized using descriptive 
summary statistics. Data collected in the trial will be summarized overall and by treatment arm. For 
continuous variables, results within each treatment arm will be su mmarized with the numbers of 
observations, mean, standard deviation, minimum, and maximum, as well as the 95% confidence 
interval for the mean. For treatment comparisons, the difference between the two treatment arms will 
be summarized with the difference of the two means and 95% confidence interval for the difference of 
the means. These calculations will be done under the assumption that the data for the two arms are 
independent and approximately normal in distribution. If not otherwise specified, the conf idence 
interval for the difference of two means is calculated assuming unequal variance between the two 
groups. If asymptotic assumptions fail, nonparametric summary statistics (medians, 25th and 75th 
percentiles) may be displayed as an alternative. In add ition, more appropriate non -parametric tests will 
be considered if the assumptions for the parametric tests are violated. For the comparison of two 
independent samples, if the data are not normally distributed, Wilcoxon rank -sum test will be 
performed inst ead of the parametric t -test.  
 
For categorical variables, results within each arm will be summarized with participant counts, 
percentages, and 95% confidence intervals. The differences between the two treatment arms will be 
summarized with the difference in percentages and the asymptotic 95% confidence interval for the 
difference of two percentages.  
 
Survival analysis techniques will be used to analyze the time -to-event variables. Survival curves will be 
constructed using Kaplan -Meier estimates. Log -rank t est results will be computed for comparison of 
survival distributions. Summary tables for safety and efficacy endpoints will include event rates (Kaplan -
Meier estimates of event rates), relative risk, confidence interval for the relative risk, the differen ce in 
means/rates, the confidence interval for difference in means/rates, and the p -value.  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   27   
For the primary efficacy endpoint,  respiratory Clearance  at Day 3 will be summarized by treatment 
group and the difference will be tested using a two -sided Fisher’s Exact Test at the 0.05 significance 
level. The corresponding confidence interval for the difference in proportions will be calculated.  
 
Every effort will be  made to ensure the oropharyngeal samples are collected at all time points specified 
by the protocol even if the subject discontinues the study drug.  The primary analytic sample will be the 
mITT cohort  
 
All analyses will be repeated using the per-protocol  population . 
 
9.4.2  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
 
Secondary Efficacy Analysis  
• Fecal viral clearing at day 14 will be summarized by treatment group and the difference will 
be tested separately for each day using a two -sided Fisher’s Exact Test.  
 
• Respirat ory viral shedding as measured on days  1, 3, 7, 10, 14 will be compared between 
treatment groups using repeated measures analysis.  
 
•            Fecal viral shedding as measured on days 1, 3, 7, 10, 14  and 21  will be compared between  
treatment groups using repeated measures analysis.  
 
We plan to consider additional analysis approaches including but not limited to: time to negative COVID -
19 test as determined by PCR using oropharyngeal  and/or fecal samples;  longitudinal analysis of 
continuous measures such as body temperature and O2 saturation;  The proportion of participants in 
each treatment group who progress to severe COVID disease will be compared using a two -sided z test 
with continuity correction. The corresponding confidence interval for the difference in proportions will 
be calculated.  
 
All secondary endpoint analyses will be performed for the mITT and PP populations at the 0.05 
significance level.  No adjustment for multiple testing will be performed . 
 
9.4.3  SAFETY ANALYSES  
  
Adverse event data will be summarized for all participants in the safety population. Site -reported serious 
adverse events and unexpected adverse drug reactions will be summarized as participant -based counts 
and percentages by AE catego ry.  
 
In addition, participant listings will be provided for serious, unexpected, and unanticipated adverse 
reactions. Any adverse events leading to discontinuation of study drug or death will also be listed for all 
participants.  
  
9.4.4  BASELINE DESCRIPTIVE  STA TISTICS  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   28  
Demographic characteristics and medical history, adverse events, COVID disease signs and symptoms 
and treatment compliance will be summarized and compared between treatment groups. The details of 
the statistical analyses will be  included in the Statistical Analysis Plan . 
 
9.4.5  PLANNED INTERIM ANAL YSES  
 
N/A 
 
9.4.6  SUB -GROUP ANALYSES  
N/A 
9.4.7  TABULATION OF INDIVI DUAL PARTICIPANT DATA  
 
N/A 
 
9.4.8  EXPLORATORY ANALYSES  
 
A detailed description of all statistical analyses will be  presented in the Statistical Analysis Plan.  
 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS  
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS .   
10.1.1  INFORMED CONSENT PRO CESS  
 
10.1.1.1  CONSENT/ASSENT AND O THER INFORMATIONAL D OCUMENTS PROVIDED TO  
PARTICIPANTS  
 
Consent describing in detail the study intervention, study procedures, and risks will be  provided  to the 
participant and documentation of informed consent will be  required prior to  administering study 
intervention s.  Non -English speakers will be enrolled u sing interpreters and IRB approved Short Forms 
per the IRB’s Short Form policy.  
 
10.1.1.2  CONSENT PROCEDURES A ND DOCUMENTATION  
 
Informed consent (IC) is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. The PI or physician co -Investigator 
will explain the research study to the participant and answer a ny questions that may arise.  Utilizing  the 
telehealth platform, an explanation will be provided in terms suited to the participant’s comprehension 
of the purposes, procedures, and potential risks of the study and of their rights as research participants.  
Potential p articipants will have the opportunity to ask question s. The participants will have the 
opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to 
participate. They will be informed that participation is voluntary and that they may withdraw from the 
study at any time,  without prejudice.  The rights and welfare of the participants will be protected by 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   29 emphasizing to them that the quality of their medical care will not be adversely affected if they decline 
to participate in this study.  
 
FDA regulations generally require t hat the informed consent of a trial participant be documented by the 
use of a written consent form that has been approved by the IRB and signed and dated by the subject at 
the time of consent (21 CFR 50.27(a)). Considering  COVID -19 infection control measur es, if the 
technology is available, current FDA guidance suggests that electronic methods of obtaining informed 
consent should be considered as follows:  
 
 To ensure that patients are approached in a consistent fashion, a standard process should be 
used that  will accomplish the following:  
 Identification of who is on the call or telemedicine visit  
 Review of the IC with the patient by the investigator (or their designee) and response to 
any questions the patient may have  
 Confirmation by the witness that the pa tient’s questions have been answered  
 Confirmation by the investigator that the patient is willing to participate in the trial and 
sign the informed consent document while the witness is listening on the phone  
 Verbal confirmation by the patient that they would like to participate in the trial and 
that they have signed and dated the informed consent document that is in their 
possession.  
 
 If the signed informed consent document cannot be collected from  the patient’s location and 
included in the study records , FDA considers the following option  acceptable to provide 
documentation that the patient signed the informed consent document:  
 A dated attestation by the witness who participated in the call and by the investigator 
that the patient confirmed that they ag reed to participate in the study and signed the 
informed consent . 
 
For this study involving participants with COVID -19 positivity, in accordance with FDA guidance , the 
following steps will be performed while obtaining the IC by phone or telehealth video chat from the 
Subject . 
 
1) Purpose of the study and the potential risks/benefits of the use of the Investigational Agent 
Niclosamide in the treatment of confirmed COVID -19 infection will discussed in detail by the 
principal investigator or sub -investigator (P I/Sub -I) with the subject prior to obtaining the IC.  
Opportunity to review the ICF (informed consent form) prior to or during the discussion will be 
provided .  Adequate time for discussion between the PI/Sub -I will be given to the potential 
participant.  After review of the IC, any questions that the potential participant ha s will be 
addressed during or after review of the IC.  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   30 2) Availability and/or possibility of other potential treatment options will be discussed with the 
participant.  
 
3) A second member of t he study team will be present on the phone or video chat during the entire 
discussion. The witness will ask  the p otential participant if they underst and the contents of the 
discussion and if they ha ve any questions  to address.  The p articipant will be infor med that they can 
ask questions at any time during the trial.  
 
4) The PI/Sub -I will sign the ICF along with the witness. Copies of the signed form w ill be placed in the 
patient’s medical record and provided to the pa rticipant .  
 
5) This document will be placed i nto the electronic medical record  and electronically signed,  and time 
stamped by the investigator. In de-identified form, it will be the study source document for 
documenting the process of obtaining ICF.   A copy of the electronically signed consent (signe d by 
the witness and investigator) is either emailed , sent by US Mail  to subject . 
10.1.2  STUDY DISCONTINUATIO N AND CLOSURE  
 
This study may be temporarily suspend ed or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be 
provided by the suspending or terminating party to study participants, investigator, funding agency , and 
regulatory authorities.  If the study is prematurely terminated or suspended, the  Principal Investigator 
(PI) will promptly inform study participants  and the Instituti onal Review Board ( IRB) for the termination 
or suspension.  Study participants will be contacted, as applicable, and be informed of changes to study 
visit schedule.  
  
Circu mstances that may warrant termination or suspension include, but are not limited to:  
 Determination of unexpected, significant, or unacceptable risk to participants  
 Insufficient compliance to protocol requirements  
 Data that are not sufficiently complete and /or evaluable  
 Determination that the primary endpoint has been met  
 
The s tudy may resume once concerns about safety, protocol compliance, and data quality are addressed  
and the IRB. 
 
10.1.3  CONFIDENTIALITY AND PRIVACY  
 
Participant confidentiality and privacy is strictly held in trust by the participating investigators, their 
staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover testing of 
biological samples in addition to the clinical information relating to participants.  Therefore, the study 
protocol, documentation, data, and all other information generated will be held in strict confidence. No 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   31 information concerning the study,  or the data will be released to any unauthorized third party without 
prior written approval of the  sponsor.  
 
All research activities will be conducted in as private a setting as possible.   The use of the telehealth 
video platform  will include participant instruction on using the platform in a private setting or with a 
family member/ significant other via Facetime as described in the Study Intervention.  
 
Representatives of the Institutional Review Board ( IRB), regulatory agencies or pharmaceutical company  
supplying study product may inspect all documents and records required to be maintained by the 
inve stigator, including but not limited to, medical and pharmacy records for the participants in this 
study.  The clinical study site will permit access to such records.  
 
The study participant’s contact information will be securely stored at each clinical site  for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements.  
The Principal Investigator will be responsible to ensure the study is conducted in accordance with the 
protocol, Good Clinical Practice (GCP), applicable regulatory requirements, and that the data recorded is 
valid. To achieve this objective, the study wil l be continuously monitored, and the study conduct 
reviewed on a weekly basis by the Study Team.  
Monitoring will be conducted to ensure that the rights and well -being of human participants are 
protected, that the reported trial data are accurate, complete,  and verifiable, and that the conduct of 
the trial follows the currently approved protocol/amendment(s), with GCP, and with applicable 
regulatory requirement(s).  
A Clinical Monitoring Plan will be created by the Study Team and will describe in detail the p ersonnel 
who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail 
monitoring will be performed, and the distribution of monitoring reports.  
 
10.1.4  FUTURE USE OF DATA  
The collection of personal patient information will be limited to the amount necessary to achieve the 
aims of the research, so that no unneeded sensitive information is being collected.  
Data from the EDC will be exported into Excel or SAS file format (password protected), which will then 
be used for data an alysis.  Only de -identified, not including the participant’s contact or identifying 
information data will be used for data analysis.  
 
10.1.5  KEY ROLES  AND STUDY GOVERNANCE  
Provide the name and contact information of the Principal Investigator . 
Principal Investigator  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   32 Harry Selker, MD  
Institute for Clinical Research and Health Policy Studies  
Tufts Clinical and Translational Science Institute (CTSI)  
Tufts University  
Tufts Medical Center  
800 Washington Street, # 63, Boston, MA 02111  
Phone: (617) 636 -5009  
Fax: (617) 636 -8023  
Email  
 
 
10.1.6  SAFETY OVERSIGHT  
An appropriately credentialled Independent Safety Monitor (ISM) without association to the trial or 
conflicts of related to the study will monitor the data on a weekly basis and make recommendations to 
the PI with respect to the:  
 Safety of the trial participants including adverse events (AEs), serious adverse events (SAE's), 
and unexpected problems  
 The Independent Safety Monitor will review and evaluate all AEs and SAEs in a blinded fashion,  
however, can be unb linded as needed.  
 The ISM will have access to unblinded SAE rates for participants randomized to niclosamide and 
placebo. Rates of non -serious AEs will also be compared between the two study groups.  
Subjects will be monitored for adverse events (AEs) and serious adverse events (SAEs). A greater than 3x 
incidence of treatment related SAEs in the niclosamide treatment group vs placebo will be added to the 
protocol as the stopping threshold  
 
The PI is personally responsible for conducting and supervising the conduct of human subject’s  research 
by protecting the rights, safety, and welfare of subjects under the investigator’s care.  The PI also must 
ensure that all the research conducted is don e so in an ethical manner and in accordance with all 
federal, state, and local laws and regulations, institutional policies/procedures, the study protocol/plan, 
and the requirements of the IRB. Oversight is defined as management by overseeing the performan ce or 
operation of a person or group, watchful care, superintendence, general supervision. Any person serving 
as a PI has voluntarily accepted these responsibilities and is expected to fully comply with these 
requirements. To provide PI oversight and to en sure that the rights, safety, and welfare of research 
subjects is protected the PI will, at a minimum, confirm:  
 Any individual to whom a task is delegated is qualified by education, training, and experience to 
perform the task.  
 There is adequate training  for all staff participating in the conduct of the study  
  The PI or another qualified individual associated with the study is available to study subjects to 
answer questions or provide care during the conduct of the research  
 All research staff adhere to th e research plan (i.e., inclusion/exclusion criteria, safety 
assessments, safety monitoring and reporting of unanticipated problems).  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   33 Expected  Oversight  Practices   
 The PI will work closely with the study team  to ensure oversight of the research study and the 
necessary documentation of such activities. A sub - Investigator can cover for the PI when he is 
unavailable or is on vacation.  
 A Delegation of Authority Log will be completed prior to opening to accrual. T his log will be 
maintained accurately during the life of the study.  
 A Training Log will be completed  prior to opening to accrual. This log will be maintained 
accurately during the life of the study.  
 The PI or delegated physician Investigator will sign -off on all study -related documents (i.e., 
eligibility verification) prior to subjects beginning study treatment per protocol  to ensure the 
safety of the study participants  
 The PI or delegated physician Investigator will evaluate and ascribe attribution, sign-off on all 
AEs and SAEs.  
 The PI and  Study Team  will establish the method in which they will consistently communicate. 
At a minimum, this is intended to be through a combination of electronic, audio, and face to 
face interactions. Details and specifics of th ese interactions will be  established by the PI and 
Study Team prior to activation of each study.  
 Communication regarding SAEs will be documented in real -time. If the PI is not available, the 
delegated physician Investigator  should be notified.  
 Regular mee tings with the PI  to discuss subject participation, including AEs and treatment, will 
be established  to ensure adequate oversight. This is in addition to the immediate availability of 
the PI, or delegated physician Investigator , to address SAE, protocol interpretation , safety 
monitoring  or other urgent clinical needs.  Involvement of the treating sub -investigator is 
recommended but not required.  
 Timely and accurate documentation of oversight is required and will be  provided by the PI 
consistent with FDA15 72. The nature of oversight documentation is through written and 
electronic means.  
 The PI or physician Investigator  will complete  urgent documents including initial SAE review and 
sign-off within 24 hours of notification of the event.  
 All non-urgent regu latory documents including IRB submission/revisions, AE attribution 
assignments, AE grading will be completed by the PI or physician Investigator within 48 hours . 
 Additional study documents including but not limited to research notes, email correspondences , 
and study logs are to be reviewed at least on a weekly basis  by the PI and included with research 
documentation.  
 
 
10.1.7  CLINICAL MONITORING  
 
Clinical monitoring will be  conducted to ensure that the rights and well -being of trial participants  are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of 
the trial is in compliance with the currently approved protocol/amendment(s), with International 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   34 Conference on Harmonisation Good Clinical Practice  (ICH GCP), and with applicable regulatory 
requirement(s).  
 
Refer to  Section 10.1.6 Safety Oversite for details.  
 
10.1.8  QUALITY ASSURANCE AND QUALITY CONTROL  
   
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated. Any missing data or data anomalies will be 
communicated to study PI or designee for resolution.  
 
Following written Standard Operating Procedures ( SOPs ), the PI and co - Investigators  will verify that the 
clinical trial is conducted,  and data are generated,  and biological specimens are collected , documented 
(recorded), and reported in compliance with the protocol, Interna tional Conference on Harmonisation 
Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory 
Practices (GLP), Good Manufacturing Practices (GMP)).  
 
The investigational site will provide direct access to all source dat a/documents, and reports for the 
purpose of monitoring , auditing and inspection by local and regulatory authorities.  
 
10.1.9  DATA  HANDLING  AND RECORD  KEEPING .  
 
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIB ILITIES  
 
Data collection is the responsibility of the Study Staff under the supervision of the Investigator . The 
Investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data 
reported.  
 
All source documents will be  completed in a neat, legible manner to ensure accurate interpretation of 
data.   
 
Any h ardcopies of study visit worksheets  will be provided for use as source document  worksheets for 
recording data for each participant enrolled in the study.  Data recorded in the electronic case report 
form ( eCRF ) derived from study source documents will be consistent with the data recorded on the 
source documents .  
 
Clinical data , AEs,  concomitant  medications,  and any other data collected from participants  will be 
entered into a REDCap database.   The data system includes password protection and internal quality 
checks, such as automatic range checks, to identify data that appear inconsistent, incom plete, or 
inaccurate. Clinical data will be entered directly from the source documents.  
 
10.1.9.2  STUDY RECORDS RETENT ION  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   35  
We will follow  the IRB’s HRP-073 - SOP - Records Retention Timeframe – Investigators  (0.03)  
 
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonisation Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP ) requirements. The 
noncompliance may be either on the part of the participa nt, the Investigator, or the Study Team . As a 
result of deviations, corrective actions are to be developed by the site and implemented promptly.  
 
These practices are consistent with ICH GCP:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
Protocol deviations will be summarized by type of deviation and treatment group. Protocol deviation 
summaries will be participant -based.  
 
10.1.11  PUBLICATION AND DATA  SHARING POLICY  
The preparation and submittal for publication of manuscripts containing the study results shall be in 
accordance with a process determined by mutual written agreement among the study Sponsor and 
participating institution s.  The publication or presentation of any study results shall comply with all 
applicable privacy laws, including, but not limited to, the Health Insurance Portability and Accountability 
Act of 1996.  
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As 
such, this trial will be registered at ClinicalTrials.gov, and results information from this trial wil l be 
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer -
reviewed journals.  
 
10.1.12  CONFLICT OF  INTEREST  POLICY  
 
The independence of this study from any actual or perceived influence, such as by the pharmaceutical 
industry, is critical.  Therefore , any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, 
persons who have a perceived conflict of int erest will be required to have such conflicts managed in a 
way that is appropriate to their participation in the design and conduct of this t rial.  The study 
leadership in conjunction has established policies and procedures for all study group members to 
disclose all conflicts of interest and will establish a mechanism for the management of all reported 
dualities of interest.  
 
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   36 10.2 ADDITIONAL CONSIDERA TIONS  
 
  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   37 10.3 ABBREVIATIONS  
 
AE Adverse Event  
ANCOVA  Analysis of Covariance  
CFR Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CRF Case Report Form  
DCC Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data Safety Monitoring Board  
DRE Disease -Related Event  
EC Ethics Committee  
eCRF  Electronic Case Report Forms  
FDA Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
FFR Federal Financial Report  
GCP Good Clinical Practice  
GLP Good Laboratory Practices  
GMP  Good Manufacturing Practices  
GWAS  Genome -Wide Association Studies  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation   
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IND Investigational New Drug Application  
IRB Institutional  Review Board  
ISM Independent Safety Monitor  
ISO International Organization for Standardization  
ITT Intention -To-Treat  
LSMEANS  Least -squares Means  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
NCT National Clinical Trial  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
OHRP  Office for Human Research Protections  
PI Principal Investigator  
QA Quality Assurance  
QC Quality Control  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   38 SMC  Safety Monitoring Committee  
SOA  Schedule of Activities  
SOC System Organ Class  
SOP Standard Operating Procedure  
UP Unanticipated Problem  
US United States  
 
  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   39 10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
 
Version  Date  Descrip tion of Change  Brief Rationale  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   40 11 REFERENCES  
1. Wu, Y., C. Guo, L. Tang, Z. Hong, J. Zhou, X. Dong, H. Yin, Q. Xiao, Y. Tang, X. Qu, L. Kuang, X. 
Fang, N. Mishra, J. Lu, H. Shan, G. Jiang, and X. Huang, Prolonged presence of SARS -CoV-2 viral 
RNA in faecal samples.  Lancet Gastroenterol Hepatol, 2020. 5(5): p. 434 -435. 7158584  
2. Jeon, S., M. Ko, J. Lee, I. Choi, S.Y. Byun, S. Park, D. Shum, and S. Kim, Identification of antiviral 
drug candidates against SARS -CoV-2 from FDA -approved drugs.  bioRxiv, 2020: p. 
2020.03.20.999730.  
3. Jung, E., S. Nam, H. Oh, S. Jun,  H.J. Ro, B. Kim, M. Kim, and Y.Y. Go, Neutralization of Acidic 
Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of the Dengue Virus Life Cycle In 
Vitro.  Sci Rep, 2019. 9(1): p. 8682. 6582152  
4. Cairns, D.M., D. Boorgu, M. Levin, and D.L. Kaplan,  Niclosamide rescues microcephaly in a 
humanized in vivo model of Zika infection using human induced neural stem cells.  Biol Open, 
2018. 7(1). 5829514  
5. Chen, W., R.A. Mook, Jr., R.T. Premont, and J. Wang, Niclosamide: Beyond an antihelminthic 
drug.  Cell Sig nal, 2018. 41: p. 89 -96. 5628105  
6. Andersen, P.I., K. Krpina, A. Ianevski, N. Shtaida, E. Jo, J. Yang, S. Koit, T. Tenson, V. Hukkanen, 
M.W. Anthonsen, M. Bjoras, M. Evander, M.P. Windisch, E. Zusinaite, and D.E. Kainov, Novel 
Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine.  
Viruses, 2019. 11(10). 6832696  
7. Fan, X., J. Xu, M. Files, J.D. Cirillo, J.J. Endsley, J. Zhou, and M.A. Endsley, Dual activity of 
niclosamide to suppress replication of integrated HIV -1 and Mycobacterium tuberculosis 
(Beijing).  Tuberculosis (Edinb), 2019. 116S : p. S28 -S33.  
8. Jurgeit, A., R. McDowell, S. Moese, E. Meldrum, R. Schwendener, and U.F. Greber, Niclosamide is 
a proton carrier and targets acidic endosomes with broad antiviral effects.  PLoS Pathog, 2012. 
8(10): p. e1002976. 3486884  
9. Marrugal -Lorenzo, J.A., A. Serna -Gallego, J. Berastegui -Cabrera, J. Pachon, and J. Sanchez -
Cespedes, Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections.  Sci Rep, 
2019. 9(1): p. 17.  6327057  
10. Wang, Y.M., J.W. Lu, C.C. Lin, Y.F. Chin, T.Y. Wu, L.I. Lin, Z.Z. Lai, S.C. Kuo, and Y.J. Ho, Antiviral 
activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission.  
Antiviral Res, 2016. 135: p. 81 -90.  
11. Xu, J., P.Y. Shi, H. Li, and J. Zhou, Broad Spectrum Antiviral Agent Niclosamide and Its 
Therapeutic Potential.  ACS Infect Dis, 2020.  
12. Xu, M., E.M. Lee, Z. Wen, Y. Cheng, W.K. Huang, X. Qian, J. Tcw, J. Kouznetsova, S.C. Ogden, C. 
Hammack, F. Jacob, H.N. N guyen, M. Itkin, C. Hanna, P. Shinn, C. Allen, S.G. Michael, A. 
Simeonov, W. Huang, K.M. Christian, A. Goate, K.J. Brennand, R. Huang, M. Xia, G.L. Ming, W. 
Zheng, H. Song, and H. Tang, Identification of small -molecule inhibitors of Zika virus infection an d 
induced neural cell death via a drug repurposing screen.  Nat Med, 2016. 22(10): p. 1101 -1107.  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   41 13. Wu, C.J., J.T. Jan, C.M. Chen, H.P. Hsieh, D.R. Hwang, H.W. Liu, C.Y. Liu, H.W. Huang, S.C. Chen, 
C.F. Hong, R.K. Lin, Y.S. Chao, and J.T. Hsu, Inhibition of s evere acute respiratory syndrome 
coronavirus replication by niclosamide.  Antimicrob Agents Chemother, 2004. 48(7): p. 2693 -6. 
434198  
14. Mazzon, M., A.M. Ortega -Prieto, D. Imrie, C. Luft, L. Hess, S. Czieso, J. Grove, J.K. Skelton, L. 
Farleigh, J.J. Bugert, E.  Wright, N. Temperton, R. Angell, S. Oxenford, M. Jacobs, R. Ketteler, M. 
Dorner, and M. Marsh, Identification of Broad -Spectrum Antiviral Compounds by Targeting Viral 
Entry.  Viruses, 2019. 11(2). 6410080  
15. Sekulovski, N., A.E. Whorton, T. Tanaka, Y. Hirota,  M. Shi, J.A. MacLean, J.R.L. Mola, K. Groesch, 
P. Diaz -Sylvester, T. Wilson, and K. Hayashi, Niclosamide suppresses macrophage induced 
inflammation in endometriosis.  Biol Reprod, 2020.  
16. Thatikonda, S., V. Pooladanda, and C.A. -O.h.o.o. Godugu, Repurposing an old drug for new use: 
Niclosamide in psoriasis -like skin inflammation.  (1097 -4652 (Electronic)).  
17. Hochmair, M., B. Rath, L. Klameth, E. Ulsperger, C. Weinlinger, A. Fazekas, A. Plangger, R. 
Zeillinger, and G. Hamilton, Effects of salinomycin and niclosa mide on small cell lung cancer and 
small cell lung cancer circulating tumor cell lines.  Invest New Drugs, 2019.  
18. Chai, W.H., Y.R. Li, S.H. Lin, Y.H. Chao, C.H. Chen, P.C. Chan, and C.H. Lin, Antihelminthic 
Niclosamide Induces Autophagy and Delayed Apoptosi s in Human Non -small Lung Cancer Cells In 
Vitro and In Vivo.  Anticancer Res, 2020. 40(3): p. 1405 -1417.  
19. Boyapally, R., G. Pulivendala, S. Bale, and C. Godugu, Niclosamide alleviates pulmonary fibrosis 
in vitro and in vivo by attenuation of epithelial -to-mesenchymal transition, matrix proteins & 
Wnt/beta -catenin signaling: A drug repurposing study.  Life Sci, 2019. 220: p. 8 -20.  
20. Cabrita, I., R. Benedetto, R. Schreiber, and K. Kunzelmann, Niclosamide repurposed for the 
treatment of inflammatory airway diseas e. JCI Insight, 2019. 4(15). 6693830  
21. Miner, K., K. Labitzke, B. Liu, P. Wang, K. Henckels, K. Gaida, R. Elliott, J.J. Chen, L. Liu, A. Leith, E. 
Trueblood, K. Hensley, X.Z. Xia, O. Homann, B. Bennett, M. Fiorino, J. Whoriskey, G. Yu, S. 
Escobar, M. Wong, T .L. Born, A. Budelsky, M. Comeau, D. Smith, J. Phillips, J.A. Johnston, J.G. 
McGivern, K. Weikl, D. Powers, K. Kunzelmann, D. Mohn, A. Hochheimer, and J.K. Sullivan, Drug 
Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A 
Antago nists That Fully Bronchodilate Airways.  (1663 -9812 (Print)).  
22. Burock, S., S. Daum, U. Keilholz, K. Neumann, W. Walther, and U. Stein, Phase II trial to 
investigate the safety and efficacy of orally applied niclosamide in patients with metachronous 
or sychr onous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.  
BMC Cancer, 2018. 18(1): p. 297. 5856000  
23. Burock, S., S. Daum, H. Tr√∂ger, T.D. Kim, S. Kr√ºger, D.T. Rieke, S. Ochsenreither, K. Welter, P. 
Herrmann, A. Sleegers, W. Walth er, U. Keilholz, and U. Stein, Niclosamide a new chemotherapy 
agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial.  
Journal of Clinical Oncology, 2018. 36(15_suppl): p. e14536 -e14536.  
24. A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative 
Proctosigmoiditis . 2018: Clinicaltrials.gov.  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   42 25. Guan, W.J., Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. He, L. Liu, H. Shan, C.L. Lei, D.S.C. Hui, B. Du, 
L.J. Li, G. Zeng, K.Y. Yuen, R.C. Chen, C .L. Tang, T. Wang, P.Y. Chen, J. Xiang, S.Y. Li, J.L. Wang, Z.J. 
Liang, Y.X. Peng, L. Wei, Y. Liu, Y.H. Hu, P. Peng, J.M. Wang, J.Y. Liu, Z. Chen, G. Li, Z.J. Zheng, S.Q. 
Qiu, J. Luo, C.J. Ye, S.Y. Zhu, and N.S. Zhong, Clinical Characteristics of Coronavir us Disease 2019 
in China.  N Engl J Med, 2020. 7092819  
26. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among 
Patients with Coronavirus Disease 2019 — United States, February 12 –March 28, 2020. .  MMWR 
Morb Mortal Wkly Rep, (6 9): p. 382 -386.  
27. Survey, N.H.I., Early release of selected estimates based on data from the 2018 National Health 
Interview Survey.  US Department of Health and Human Services, CDC, 2020.  
28. Jin, X., J.S. Lian, J.H. Hu, J. Gao, L. Zheng, Y.M. Zhang, S.R. Hao, H.Y. Jia, H. Cai, X.L. Zhang, G.D. 
Yu, K.J. Xu, X.Y. Wang, J.Q. Gu, S.Y. Zhang, C.Y. Ye, C.L. Jin, Y.F. Lu, X. Yu, X.P. Yu, J.R. Huang, K.L. 
Xu, Q. Ni, C.B. Yu, B. Zhu, Y.T. Li, J. Liu, H. Zhao, X. Zhang, L. Yu, Y.Z. Guo, J.W. Su, J.J. Tao, G.J. 
Lang, X.X.  Wu, W.R. Wu, T.T. Qv, D.R. Xiang, P. Yi, D. Shi, Y. Chen, Y. Ren, Y.Q. Qiu, L.J. Li, J. 
Sheng, and Y. Yang, Epidemiological, clinical and virological characteristics of 74 cases of 
coronavirus -infected disease 2019 (COVID -19) with gastrointestinal symptom s. Gut, 2020. 
7133387  
29. Hamming, I., W. Timens, M.L. Bulthuis, A.T. Lely, G. Navis, and H. van Goor, Tissue distribution of 
ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS 
pathogenesis.  J Pathol, 2004. 203(2): p . 631 -7. 7167720  
30. Chang, Y. -W., T. -K. Yeh, K. -T. Lin, W. -C. Chen, H. -T. Yao, S. -J. Lan, Y. -S. Wu, H. -P. Hsieh, C. -M. 
Chen, and C. -T. Chen, Pharmacokinetics of Anti -SARS -CoV Agent Niclosamide and Its Analogs in 
Rats.  Journal of Food and Drug Analysis, 2006. 14.  
31. Zhang, J.L., H.F. Si, X.F. Shang, X.K. Zhang, B. Li, X.Z. Zhou, and J.Y. Zhang, New life for an old 
drug: In vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii 
RH strain.  Int J Parasitol Drugs Drug Resist, 2019. 9: p. 27 -34. 6312869  
32. Domalaon, R., P.M. De Silva, A. Kumar, G.G. Zhanel, and F. Schweizer, The Anthelmintic Drug 
Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram -Negative Bacilli.  
Antimicrob Agents Chemother, 2019. 63(4). 643751 6 
33. Tam, J., T. Hamza, B. Ma, K. Chen, G.L. Beilhartz, J. Ravel, H. Feng, and R.A. Melnyk, Host -
targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without 
disrupting the gut microbiota.  Nat Commun, 2018. 9(1): p. 5233. 6286312  
34. Farkouh, M.E., M. Domanski, G.D. Dangas, L.C. Godoy, M.J. Mack, F.S. Siami, T.H. Hamza, B. 
Shah, G.G. Stefanini, M.S. Sidhu, J.F. Tanguay, K. Ramanathan, S.K. Sharma, J. French, W. Hueb, 
D.J. Cohen, and V. Fuster, Long -Term Survival Following Multivessel R evascularization in Patients 
With Diabetes: The FREEDOM Follow -On Study.  J Am Coll Cardiol, 2019. 73(6): p. 629 -638. 
6839829  
35. Hatamipour, M., M.R. Jaafari, A.A. Momtazi -Borojeni, M. Ramezani, and A. Sahebkar, 
Development, characterization and evaluation of in vivo anti -tumor activity of niclosamide 
nanoliposomes against colon carcinoma.  Curr Mol Pharmacol, 2019.  
NIC for COVID  Version 7.0  
Protocol  00000605  
Selker PI  01022021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   43 36. Hatamipour, M., M.R. Jaafari, A.A. Momtazi -Borojeni, M. Ramezani, and A. Sahebkar, 
Nanoliposomal Encapsulation Enhances In Vivo Anti -Tumor Activity  of Niclosamide against 
Melanoma.  Anticancer Agents Med Chem, 2019. 19(13): p. 1618 -1626.  
37. Huang C, wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel 
coronavirus in Wuhan, China. Lancet 395: 497 -506.  
38. Ding S, Lian TJ. (2020)  Is SARS -CoV-2 Also an Enteric Pathogen With Potential Fecal – Oral 
Transmission? A COVID -19 Virological and Clinical Review. Gastroenterology. 5: 1 -9. 
39. Lescure, Francois -Xavier et al. (2020) Clinical and virological data of the first cases of COVID -19 
in Eu rope: a case series. The Lancet Infectious Diseases. 20(6):697 – 706. 
40. Luo, F., Luo, M., Rong, Q. et al. Niclosamide, an antihelmintic drug, enhances efficacy of PD -
1/PD -L1 immune checkpoint blockade in non -small cell lung cancer. j. immunotherapy cancer 7,  
245 (2019). https://doi.org/10.1186/s40425 -019-0733 -7. 
41. Azzi L, Carcano G, Dalla Gasperina D, Sessa F, Maurino V, Baj A. Two cases of COVID -19 with 
positive salivary and negative pharyngeal or respiratory swabs at hospital discharge: A rising 
concern [publ ished online ahead of print, 2020 Apr 25].  Oral Dis . 2020;10.1111/odi.13368. 
doi:10.1111/odi.13368  
42. Wyllie, A.L., Fournier, J., Casanovas -Massana, A., Campbell, M., Tokuyama, M., Vijayakumar, P., 
Geng, B., Muenker, M.C., Moore, A.J., Vogels, C.B. and Petron e, M.E., 2020. Saliva is more 
sensitive for SARS -CoV-2 detection in COVID -19 patients than nasopharyngeal swabs.  Medrxiv . 
 
 
 